| Primary |
| Prostate Cancer |
35.6% |
| Pain |
11.6% |
| Hypertension |
9.8% |
| Product Used For Unknown Indication |
9.5% |
| Prostate Cancer Metastatic |
4.4% |
| Arrhythmia |
2.9% |
| Routine Health Maintenance |
2.9% |
| Depression |
2.5% |
| Diabetes Mellitus |
2.5% |
| Prophylaxis |
2.5% |
| Constipation |
2.2% |
| Nausea |
2.2% |
| Atrial Fibrillation |
1.8% |
| Bone Pain |
1.5% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Hypercholesterolaemia |
1.5% |
| Sleep Disorder |
1.5% |
| Supplementation Therapy |
1.5% |
| Arthralgia |
1.1% |
| Asthma |
1.1% |
|
| Malignant Neoplasm Progression |
16.3% |
| Death |
10.2% |
| Vomiting |
10.2% |
| Tremor |
8.2% |
| Weight Decreased |
6.1% |
| Acute Myocardial Infarction |
4.1% |
| Completed Suicide |
4.1% |
| General Physical Health Deterioration |
4.1% |
| Lung Disorder |
4.1% |
| Oedema Peripheral |
4.1% |
| Pneumonia |
4.1% |
| Renal Failure |
4.1% |
| Subdural Haematoma |
4.1% |
| Toxicity To Various Agents |
4.1% |
| Agitation |
2.0% |
| Arrhythmia |
2.0% |
| Asthma |
2.0% |
| Cerebral Haemorrhage |
2.0% |
| Colonic Abscess |
2.0% |
| Disturbance In Attention |
2.0% |
|
| Secondary |
| Prostate Cancer |
23.8% |
| Hypertension |
9.9% |
| Pain |
7.9% |
| Prostate Cancer Metastatic |
7.9% |
| Product Used For Unknown Indication |
6.6% |
| Supplementation Therapy |
6.6% |
| Depression |
4.6% |
| Asthma |
4.0% |
| Back Pain |
4.0% |
| Hypersensitivity |
4.0% |
| Coronary Artery Insufficiency |
2.6% |
| Eczema |
2.6% |
| Arrhythmia |
2.0% |
| Cardiovascular Event Prophylaxis |
2.0% |
| Emphysema |
2.0% |
| Metastases To Bone |
2.0% |
| Osteoporosis |
2.0% |
| Osteoporosis Prophylaxis |
2.0% |
| Sleep Disorder |
2.0% |
| Antiplatelet Therapy |
1.3% |
|
| Lung Disorder |
8.8% |
| Myocardial Infarction |
8.8% |
| Sleep Disorder |
8.8% |
| Transaminases Increased |
8.8% |
| Weight Decreased |
8.8% |
| Oesophagitis |
5.9% |
| Subdural Haematoma |
5.9% |
| Toxicity To Various Agents |
5.9% |
| Trifascicular Block |
5.9% |
| Arrhythmia |
2.9% |
| Diarrhoea |
2.9% |
| General Physical Health Deterioration |
2.9% |
| Hospitalisation |
2.9% |
| Hypersensitivity |
2.9% |
| Jaundice |
2.9% |
| Ocular Icterus |
2.9% |
| Off Label Use |
2.9% |
| Pain In Extremity |
2.9% |
| Paraesthesia |
2.9% |
| Phlebitis |
2.9% |
|
| Concomitant |
| Supplementation Therapy |
24.2% |
| Prostate Cancer |
21.2% |
| Prostate Cancer Metastatic |
12.1% |
| Hypertension |
9.1% |
| Hormone-refractory Prostate Cancer |
6.1% |
| Metastases To Bone |
6.1% |
| Product Used For Unknown Indication |
6.1% |
| Chronic Obstructive Pulmonary Disease |
3.0% |
| Hypercholesterolaemia |
3.0% |
| Pain |
3.0% |
| Prophylaxis |
3.0% |
| Thrombosis |
3.0% |
|
| Fatigue |
12.5% |
| Haemorrhagic Stroke |
12.5% |
| Liver Function Test Abnormal |
12.5% |
| Metastases To Central Nervous System |
12.5% |
| Osteonecrosis Of Jaw |
12.5% |
| Swelling |
12.5% |
| Thrombocytopenia |
12.5% |
| Underdose |
12.5% |
|
| Interacting |
| Product Used For Unknown Indication |
80.0% |
| Metastases To Bone |
20.0% |
|
|
